Clinical Trial Update: EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly in Semi-immune Adults [Phase 1]

View source ↗

Summary

Phase 1 trial assessing the intramuscular EBA-175 RII-NG malaria vaccine in semi-immune adults has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plasmodium Falciparum Malaria

Drugs mentioned

• EBA-175 RII-NG malaria vaccine (EBA-175 RII-NG malaria vaccine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Plasmodium Falciparum Malaria | Phase 1 | Status: COMPLETED